Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134037) titled 'A Study of Ivonescimab (AK112) Given Before Surgery for Resectable Esophageal Squamous Cell Carcinoma' on Oct. 10.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Fujian Medical University Union Hospital
Condition:
Resectable esophageal squamous cell carcinoma (ESCC), clinical stage cT2-4aN0-3M0 (stage II-IVA)
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-10-15
Target Sample Size: Ivonescimab Neoadjuvant Monotherapy Group:28;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=343482
Disclaimer: Cu...